Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelabresib add-on to stable ruxolitinib in Japanese adults with myelofibrosis
jRCT2011250070Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pelabresib and ruxolitinib in myelofibrosis (MF), sponsored by Novartis. Primary endpoints: Incidence of dose-limiting toxicities and Incidence and severity of adverse events and serious adverse events. Started May 2026; status: active, not recruiting.
02
Drugs
pelabresibruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT2011250070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250070.